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The potential for cross-reaction between Cryptococcus neoformans and Histoplasma capsulatum in antigen
assays was evaluated. We tested patient samples, spleens from infected mice, and purified polysaccharides in
the MVista Histoplasma antigen enzyme immunoassay and cryptococcal antigen latex agglutination system for
cross-reactivity, and none was observed.
The diagnosis of invasive or systemic mycosis is often ac-
complished through the detection of polysaccharide antigens
in body fluids by immunologic assays. The specific polysaccha-
rides detected are galactomannans (GalM) of Aspergillus spp.
(2) and Histoplasma capsulatum (1) and glucuronoxylomannan
(GXM) of Cryptococcus neoformans (2). We have observed
several cases in which tests for both cryptococcal GXM and
Histoplasma GalM were positive and where dual infections
were documented. However, the literature on dual infection is
not extensive (3). This prompted us to investigate further the
presence of cross-reactivity between cryptococcal GXM and
Histoplasma GalM.
Cryptococcal antigen latex agglutination system (CALAS)
kits were purchased from Meridian Bioscience (Cincinnati,
OH) and used according to the manufacturer’s instructions.
The serum samples were treated with pronase before being
tested with a CALAS kit. The MVista Histoplasma antigen
enzyme immunoassay (EIA) was performed at MiraVista Di-
agnostics (Indianapolis, IN) as previously reported (1).
Histoplasma and Cryptococcus polysaccharide antigens were
prepared and purified as previously described (1, 2). His-
toplasma GalM and cryptococcal GXM, galactoxylomannan,
and capsular polysaccharide were tested at a concentration of
1 g/ml, and the CALAS kit positive control was tested undi-
luted. Cryptococcal GXM, galactoxylomannan, and capsular
polysaccharide and the CALAS control were strongly positive
(agglutination score of 3 or 4) by CALAS assay but nega-
tive in the Histoplasma antigen EIA. Conversely, Histoplasma
GalM was positive in the Histoplasma antigen EIA (39 ng/
ml) but negative by CALAS assay.
Twenty-nine residual serum specimens from 15 patients with
progressive disseminated histoplasmosis were tested by CALAS
assay, in a study approved by the institutional review board of
Clarian Hospital, Indianapolis, IN. All had underlying immu-
nosuppression, including AIDS in 10, organ transplantation in
2, and miscellaneous causes in 3 patients. The basis for diag-
nosis of histoplasmosis was Histoplasma antigenemia and anti-
genuria in seven cases, culture in six cases, and histopathology
in two cases. Histoplasma antigenemia ranged from 0.6 to
39 ng/ml (median, 2.5 ng/ml). No samples were positive by
CALAS assay (Table 1).
Residual serum or cerebrospinal fluid samples from 25 pa-
tients with cryptococcosis were previously described (2). The
CALAS assay was positive for 24 of 25 patients, at titers of 1:1
to 1:65,536 (median, 1:1,024). Culture was the basis for diag-
nosis for the 25th patient. None of the samples were positive in
the Histoplasma antigen EIA (Table 1).
In a previously described murine histoplasmosis model (4),
eight B6C3F1 mice were infected intranasally with 1  106 H.
capsulatum organisms and euthanized on day 10 of infection
according to institutional guidelines (4). Spleen tissue was ho-
mogenized in 2 ml of RPMI medium and tested in the His-
toplasma antigen EIA following 10-fold dilution but used un-
diluted in the CALAS assay. Spleen tissues contained high
levels of Histoplasma antigen but were negative by CALAS
assay (Table 1).
In a cryptococcal experimental infection model (2), 12
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TABLE 1. Cross-reactivity in clinical specimens and
experimental infection
Sample type
No. of positive samples/total no. of samples
(% positive, 95% confidence interval)
Histoplasma antigen EIA CALAS assay
Histoplasmosis samples
Human serum 29/29 (100, 88.3–100) 0/29 (0, 0–11.7)b
Murine spleena 8/8 (100, 67.6–100) 0/8 (0, 0–32.4)b
Cryptococcosis samples
Human serum or
cerebrospinal fluid
0/25 (0, 0–13.3) 24/25 (96, 80.5–99.3)b
Murine spleena 0/12 (0, 0–24.2) 12/12 (100, 75.8–100)b
a Spleen tissues from mice infected with H. capsulatum were tested in the
Histoplasma antigen EIA at a 1:10 dilution and were used undiluted in the
CALAS assay. Spleen tissues of mice with cryptococcosis were tested undiluted.
b P  0.001 for comparison of Histoplasma antigen EIA and CALAS assay,
using Fisher’s exact test.
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BALB/c mice were infected intravenously with 1  104 C.
neoformans strain 24067 organisms and then euthanized on day
7 of infection. The spleen tissue was homogenized in 2 ml of
RPMI medium and tested undiluted in the Histoplasma anti-
gen EIA and the CALAS assay. Spleen tissues were positive by
CALAS assay but negative in the Histoplasma antigen EIA.
In conclusion, no cross-reactivity between Histoplasma
GalM and cryptococcal polysaccharides was observed. When
both the CALAS assay and MVista Histoplasma antigen EIA
are positive, dual infection should be suspected. Note that
these findings should not be extrapolated to other Histoplasma
or cryptococcal antigen assays.
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